Table 3.
Association between VTE and mortality in US veterans diagnosed with MM between September 1, 1999 and June 30, 2014
| 6‐mo mortality | 12‐mo mortality | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| VTE (time varying) | 1.63 | 1.18‐2.37 | <.001 | 1.22 | 0.93‐1.60 | .16 |
| Year of diagnosis | 1.00 | 0.98‐1.03 | .84 | 1.00 | 0.98‐1.02 | .74 |
| BMI | ||||||
| < 18.5 | 1.79 | 1.28‐2.52 | <.001 | 1.53 | 1.14‐2.06 | .01 |
| 18.5‐25 | Referent | Referent | ||||
| 25‐30 | 0.81 | 0.69‐0.96 | .01 | 0.79 | 0.69‐0.90 | <.001 |
| ≥ 30 | 0.72 | 0.60‐0.87 | <.001 | 0.74 | 0.64‐0.86 | <.001 |
| Age (per y) | 1.01 | 1.00‐1.02 | .03 | 1.01 | 1.00‐1.01 | .02 |
| Race | ||||||
| Non‐Black | Referent | Referent | ||||
| Black | 0.78 | 0.67‐0.92 | <.001 | 0.74 | 0.65‐0.84 | <.001 |
| Charlson Comorbidity Index, per point | 1.08 | 1.06‐1.11 | <.001 | 1.07 | 1.05‐1.09 | <.001 |
| Baseline laboratory data | ||||||
| Hemoglobin < 10 g/dL | 1.15 | 0.99‐1.33 | .06 | 1.17 | 1.04‐1.32 | .01 |
| CrCl < 30 mL/min | 1.48 | 1.26‐1.73 | <.001 | 1.31 | 1.15‐1.50 | <.001 |
| Albumin ≤ 3 g/dL | 1.70 | 1.47‐1.98 | <.001 | 1.60 | 1.42‐1.81 | <.001 |
| Albumin unknown | 0.70 | 0.54‐0.91 | .01 | 0.70 | 0.57‐0.86 | <.001 |
| Myeloma‐specific therapy | ||||||
| Transplant | NE | <.001 | 0.03‐0.14 | <.001 | ||
| Thalidomide | 0.66 | 0.55‐0.79 | .11 | 0.66 | 0.58‐0.76 | <.001 |
| Bortezomib | 0.85 | 0.69‐1.04 | <.001 | 0.82 | 0.70‐0.96 | .01 |
| Lenalidomide | 0.42 | 0.32‐0.55 | .06 | 0.45 | 0.38‐0.55 | <.001 |
| Number of therapies in first regimen | 0.71 | 0.61‐0.82 | <.001 | 0.71 | 0.61‐0.82 | <.001 |